XML 83 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash $ 86,128 $ 170,405
Restricted cash 20,000 20,000
Accounts receivable 18,976 18,976
Prepaid & other current assets 9,107 62,356
Total current assets 134,211 271,737
In process R&D 1,101,760 1,101,760
Goodwill, net 2,788,230 5,988,230
Investment in GMP Bio at fair value 22,653,225 22,653,225
Total assets 26,677,426 30,014,952
Current liabilities:    
Accounts payable and accrued liabilities 2,437,167 2,437,321
Contingent Consideration 2,625,000 2,625,000
Derivative liability on notes 703,616 423,214
Total current liabilities 19,199,914 16,504,947
Convertible long-term debt, net of costs 1,898,468
Total liabilities 19,199,914 18,403,415
Commitments and contingencies (Note 13)
Stockholders’ equity:    
Common stock, $.01 par  value; 750,000,000  shares authorized; 407,289,618 and 399,184,128 issued and outstanding, respectively 4,072,899 3,991,839
Additional paid-in capital 42,219,400 41,655,026
Accumulated deficit (38,040,668) (33,516,736)
Total Oncotelic Therapeutics, Inc. stockholders’ equity 8,251,631 12,130,129
Non-controlling interests (774,119) (518,592)
Total stockholders’ equity 7,477,512 11,611,537
Total liabilities and stockholders’ equity 26,677,426 30,014,952
Related Party [Member]    
Current liabilities:    
Accounts payable - related party 346,057 344,099
Convertible debt and short-term debt, net of costs 3,297,208 2,608,356
Nonrelated Party [Member]    
Current liabilities:    
Convertible debt and short-term debt, net of costs $ 9,790,866 $ 8,066,957